High-avidity CD8+ T cells
The primary goal of vaccination is the establishment of protective immunity. Thus there has been significant effort put toward the identification of attributes of the immune response that are associated with optimal protection. Although the number of virus-specific cells elicited is unquestionably important, recent studies have identified an additional parameter, functional avidity, as critical in determining the efficiency of viral clearance. T-cell avidity is a measure of the sensitivity of a cell to peptide antigen. High-avidity cells are those that can recognize antigen-presenting cells (APC) bearing very low levels of peptide antigen, whereas low-avidity cells require much higher numbers of peptide major histocompatibility complex (MHC) complexes in order to become activated or exert effector function. We are only now beginning to gain insights into the molecular control of avidity and the signals required for the optimal activation, expansion, and retention of high-avidity cells in vivo. This review summarizes the current knowledge regarding CD8+ T-cell avidity and explores some of the important issues that are, as of yet, unresolved.
Key WordsAvidity Viral clearance CD8+ T cells Tumors Regulation
Unable to display preview. Download preview PDF.
- 14.al Ramadi BK, Jelonek MT, Boyd LF, Margulies DH, Bothwell AL: Lack of strict correlation of functional sensitization with the apparent affinity of MHC/peptide complexes for the TCR. J Immunol 1995;155:662–673.Google Scholar
- 15.Echchakir H, Dorothee G, Vergnon I, Menez J, Chouaib S, Mami-Chouaib F: Cytotoxic T lymphocytes directed against a tumor-specific mutated antigen display similar HLA tetramer binding but distinct functional avidity and tissue distribution. Proc Natl Acad Sci USA 2002; 99:9358–9363.PubMedCrossRefGoogle Scholar
- 41.Gallimore A, Glithero A, Godkin A, Tissot AC, Pluckthun A, Elliott T, et al.: Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes. J Exp Med 1998;187:1383–1393.PubMedCrossRefGoogle Scholar
- 47.Xiong Y, Luscher MA, Altman JD, Hulsey M, Robinson HL, Ostrowski M, et al.: Simian immunodeficiency virus (SIV) infection of a rhesus macaque in duces SIV-specific CD8+T cells with a defect in effector function that is reversible on extended interleukin-2 incubation. J Virol 2001;75:3028–3033.PubMedCrossRefGoogle Scholar
- 48.Alexander-Miller MA, Derby MA, Sarin A, Henkart PA, Berzofsky JA: Supraoptimal peptide-major histocompatibility complex causes a decrease in bc1-2 levels and allows tumor necrosis factor alpha receptor II-mediated apoptosis of cytotoxic T lymphocytes. J Exp Med 1998;188:1391–1399.PubMedCrossRefGoogle Scholar